Literature DB >> 21992793

Targeting radiation-induced G(2) checkpoint activation with the Wee-1 inhibitor MK-1775 in glioblastoma cell lines.

Bhaswati Sarcar1, Soumen Kahali, Antony H Prabhu, Stuart D Shumway, Yang Xu, Tim Demuth, Prakash Chinnaiyan.   

Abstract

The purpose of this study was to determine the capacity of MK-1775, a potent Wee-1 inhibitor, to abrogate the radiation-induced G(2) checkpoint arrest and modulate radiosensitivity in glioblastoma cell models and normal human astrocytes. The radiation-induced checkpoint response of established glioblastoma cell lines, glioblastoma neural stem (GNS) cells, and astrocytes were determined in vitro by flow cytometry and in vivo by mitosis-specific staining using immunohistochemistry. Mechanisms underlying MK-1775 radiosensitization were determined by mitotic catastrophe and γH2AX expression. Radiosensitivity was determined in vitro by the clonogenic assay and in vivo by tumor growth delay. MK-1775 abrogated the radiation-induced G(2) checkpoint and enhanced radiosensitivity in established glioblastoma cell lines in vitro and in vivo, without modulating radiation response in normal human astrocytes. MK-1775 appeared to attenuate the early-phase of the G(2) checkpoint arrest in GNS cell lines, although the arrest was not sustained and did not lead to increased radiosensitivity. These results show that MK-1775 can selectively enhance radiosensitivity in established glioblastoma cell lines. Further work is required to determine the role Wee-1 plays in checkpoint activation of GNS cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21992793      PMCID: PMC5753756          DOI: 10.1158/1535-7163.MCT-11-0469

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  21 in total

1.  Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.

Authors:  Y Wang; J Li; R N Booher; A Kraker; T Lawrence; W R Leopold; Y Sun
Journal:  Cancer Res       Date:  2001-11-15       Impact factor: 12.701

2.  The wee1 protein kinase is required for radiation-induced mitotic delay.

Authors:  R Rowley; J Hudson; P G Young
Journal:  Nature       Date:  1992-03-26       Impact factor: 49.962

3.  mik1 and wee1 cooperate in the inhibitory tyrosine phosphorylation of cdc2.

Authors:  K Lundgren; N Walworth; R Booher; M Dembski; M Kirschner; D Beach
Journal:  Cell       Date:  1991-03-22       Impact factor: 41.582

4.  Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma.

Authors:  Michael T Milano; Paul Okunieff; Rosemary S Donatello; Nimish A Mohile; Joohee Sul; Kevin A Walter; David N Korones
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-06       Impact factor: 7.038

5.  In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma.

Authors:  Shahryar E Mir; Philip C De Witt Hamer; Przemek M Krawczyk; Leonora Balaj; An Claes; Johanna M Niers; Angela A G Van Tilborg; Aeilko H Zwinderman; Dirk Geerts; Gertjan J L Kaspers; W Peter Vandertop; Jacqueline Cloos; Bakhos A Tannous; Pieter Wesseling; Jacob A Aten; David P Noske; Cornelis J F Van Noorden; Thomas Würdinger
Journal:  Cancer Cell       Date:  2010-09-14       Impact factor: 31.743

6.  Wild-type TP53 inhibits G(2)-phase checkpoint abrogation and radiosensitization induced by PD0166285, a WEE1 kinase inhibitor.

Authors:  Jun Li; Yuli Wang; Yi Sun; Theodore S Lawrence
Journal:  Radiat Res       Date:  2002-03       Impact factor: 2.841

Review 7.  G2 checkpoint abrogators as anticancer drugs.

Authors:  Takumi Kawabe
Journal:  Mol Cancer Ther       Date:  2004-04       Impact factor: 6.261

8.  Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens.

Authors:  Steven M Pollard; Koichi Yoshikawa; Ian D Clarke; Davide Danovi; Stefan Stricker; Roslin Russell; Jane Bayani; Renee Head; Marco Lee; Mark Bernstein; Jeremy A Squire; Austin Smith; Peter Dirks
Journal:  Cell Stem Cell       Date:  2009-06-05       Impact factor: 24.633

9.  Dose translation from animal to human studies revisited.

Authors:  Shannon Reagan-Shaw; Minakshi Nihal; Nihal Ahmad
Journal:  FASEB J       Date:  2007-10-17       Impact factor: 5.191

10.  Activation of the unfolded protein response contributes toward the antitumor activity of vorinostat.

Authors:  Soumen Kahali; Bhaswati Sarcar; Bin Fang; Eli S Williams; John M Koomen; Philip J Tofilon; Prakash Chinnaiyan
Journal:  Neoplasia       Date:  2010-01       Impact factor: 5.715

View more
  51 in total

1.  Targeting protein neddylation with an NEDD8-activating enzyme inhibitor MLN4924 induced apoptosis or senescence in human lymphoma cells.

Authors:  Yanchun Wang; Zhongguang Luo; Yongfu Pan; Weige Wang; Xiaoyan Zhou; Lak Shin Jeong; Yiwei Chu; Jie Liu; Lijun Jia
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

2.  Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer.

Authors:  David Karnak; Carl G Engelke; Leslie A Parsels; Tasneem Kausar; Dongping Wei; Jordan R Robertson; Katherine B Marsh; Mary A Davis; Lili Zhao; Jonathan Maybaum; Theodore S Lawrence; Meredith A Morgan
Journal:  Clin Cancer Res       Date:  2014-08-12       Impact factor: 12.531

3.  Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors.

Authors:  Suzanne Leijen; Robin M J M van Geel; Anna C Pavlick; Raoul Tibes; Lee Rosen; Albiruni R Abdul Razak; Raymond Lam; Tim Demuth; Shelonitda Rose; Mark A Lee; Tomoko Freshwater; Stuart Shumway; Li Wen Liang; Amit M Oza; Jan H M Schellens; Geoffrey I Shapiro
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

4.  Neddylation inhibitor MLN4924 induces G2 cell cycle arrest, DNA damage and sensitizes esophageal squamous cell carcinoma cells to cisplatin.

Authors:  Shan Lin; Zhaoyang Shang; Shuo Li; Peng Gao; Yi Zhang; Shuaiheng Hou; Peng Qin; Ziming Dong; Tao Hu; Ping Chen
Journal:  Oncol Lett       Date:  2017-12-14       Impact factor: 2.967

5.  Enhancing direct cytotoxicity and response to immune checkpoint blockade following ionizing radiation with Wee1 kinase inhibition.

Authors:  Priya Patel; Lily Sun; Yvette Robbins; Paul E Clavijo; Jay Friedman; Christopher Silvin; Carter Van Waes; John Cook; James Mitchell; Clint Allen
Journal:  Oncoimmunology       Date:  2019-07-19       Impact factor: 8.110

6.  PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer.

Authors:  Ankita Jhuraney; Nicholas T Woods; Gabriela Wright; Lily Rix; Fumi Kinose; Jodi L Kroeger; Elizabeth Remily-Wood; W Douglas Cress; John M Koomen; Stephen G Brantley; Jhanelle E Gray; Eric B Haura; Uwe Rix; Alvaro N Monteiro
Journal:  Mol Cancer Ther       Date:  2016-05-11       Impact factor: 6.261

7.  Quantitative Phosphoproteomics Reveals Wee1 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma.

Authors:  Rebecca S Lescarbeau; Liang Lei; Katrina K Bakken; Peter A Sims; Jann N Sarkaria; Peter Canoll; Forest M White
Journal:  Mol Cancer Ther       Date:  2016-05-17       Impact factor: 6.261

Review 8.  WEE1 tyrosine kinase, a novel epigenetic modifier.

Authors:  Kiran Mahajan; Nupam P Mahajan
Journal:  Trends Genet       Date:  2013-03-26       Impact factor: 11.639

9.  Abrogating G₂/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma.

Authors:  Paola Indovina; Eleonora Marcelli; Domenico Di Marzo; Nadia Casini; Iris Maria Forte; Francesca Giorgi; Luigi Alfano; Francesca Pentimalli; Antonio Giordano
Journal:  Cancer Biol Ther       Date:  2014-01-14       Impact factor: 4.742

10.  Expression and prognostic value of the WEE1 kinase in gliomas.

Authors:  Darija Music; Rikke Hedegaard Dahlrot; Simon Kjær Hermansen; Jacob Hjelmborg; Karin de Stricker; Steinbjørn Hansen; Bjarne Winther Kristensen
Journal:  J Neurooncol       Date:  2016-01-06       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.